

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
THIRD QUARTER
2009

EQUITY INCOME FROM AFFILIATES (millions of dollars)

| | 3Q `09 | 3Q `08 | YTD 2009 | YTD 2008 |
|-------------------------|-----------------|-----------------|-------------------|-------------------|
| MERCK / SCHERING-PLOUGH | \$ 391.3 | \$ 400.2 | \$ 1,044.5 | \$ 1,158.2 |
| ASTRAZENECA LP | 191.4 | 139.1 | 482.6 | 331.6 |
| Other ⁽¹⁾ | 105.5 | 126.3 | 334.1 | 350.9 |
| TOTAL | \$ 688.2 | \$ 665.6 | \$ 1,861.2 | \$ 1,840.7 |

⁽¹⁾ Primarily reflects results for Sanofi Pasteur MSD, Johnson & Johnson^oMerck Consumer Pharmaceuticals and Merial Limited (until disposition on September 17, 2009).

JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a "NET" basis.

| | Period from July 1, 2009 until Sept. 17, 2009 | 3Q `08 | Period from Jan. 1, 2009 until Sept. 17, 2009 | YTD 2008 |
|--------------------------------------|--|-----------------|--|-------------------|
| Merial ⁽¹⁾ | | | | |
| FRONTLINE, other fipronil | \$ 197.5 | \$ 253.3 | \$ 783.9 | \$ 901.0 |
| BIOLOGICALS | 164.4 | 198.0 | 524.5 | 580.9 |
| IVOMEC, HEARTGARD, other avermectins | 91.3 | 128.6 | 341.4 | 415.0 |
| Other Animal Health | 61.0 | 72.1 | 199.7 | 220.8 |
| TOTAL MERIAL SALES | \$ 514.2 | \$ 652.0 | \$ 1,849.5 | \$ 2,117.7 |

⁽¹⁾ On September 17, 2009, Merck sold its ownership interest in Merial Limited. Sales figures for 2009 are reported until the date of disposition.

| | 3Q `09 | 3Q `08 | YTD 2009 | YTD 2008 |
|---------------------------------------|-----------------|-----------------|-------------------|-------------------|
| Sanofi Pasteur MSD | | | | |
| GARDASIL | \$ 108.1 | \$ 220.1 | \$ 417.1 | \$ 694.1 |
| FLU VACCINES | 167.1 | 117.2 | 167.1 | 117.2 |
| OTHER VIRAL VACCINES | 26.6 | 28.9 | 78.9 | 80.7 |
| HEPATITIS VACCINES | 10.3 | 19.3 | 34.7 | 56.7 |
| ROTATEQ | 10.7 | 7.9 | 29.5 | 21.2 |
| Other Vaccines | 173.0 | 173.4 | 425.0 | 438.3 |
| TOTAL SANOFI PASTEUR MSD SALES | \$ 495.8 | \$ 566.8 | \$ 1,152.3 | \$ 1,408.2 |

| | 3Q `09 | 3Q `08 | YTD 2009 | YTD 2008 |
|--|-------------------|-------------------|-------------------|-------------------|
| Merck / Schering-Plough Collaboration | | | | |
| VYTORIN | \$ 514.1 | \$ 567.2 | \$ 1,500.0 | \$ 1,810.5 |
| ZETIA | 514.5 | 534.3 | 1,507.3 | 1,676.4 |
| TOTAL MERCK / SCHERING-PLOUGH SALES | \$ 1,028.6 | \$ 1,101.5 | \$ 3,007.3 | \$ 3,486.9 |

OTHER (INCOME) EXPENSE, NET (millions of dollars)

| | 3Q `09 | 3Q `08 | YTD 2009 | YTD 2008 |
|---------------------------|---------------------|----------------|---------------------|---------------------|
| INTEREST INCOME | \$ (33.4) | \$ (171.3) | \$ (199.6) | \$ (484.2) |
| INTEREST EXPENSE | 130.7 | 71.4 | 290.9 | 194.6 |
| EXCHANGE LOSSES (GAINS) | 0.5 | 52.3 | (3.0) | 73.6 |
| Other, net ⁽¹⁾ | (2,888.9) | 78.2 | (2,943.0) | (2,075.3) |
| TOTAL | \$ (2,791.1) | \$ 30.6 | \$ (2,854.7) | \$ (2,291.3) |

⁽¹⁾ Other, net in the third quarter and first nine months of 2009 primarily reflects a \$2.8 billion gain on the sale of the Company's ownership interest in Merial Limited. Other, net in the first nine months of 2008 primarily reflects a \$2.2 billion gain on distribution from AstraZeneca LP.

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
THIRD QUARTER
2009

NET PRODUCT SALES DETAIL (millions of dollars)

| PRODUCT | 3Q '09 vs. 3Q '08 | | | | | |
|-------------------------------------|-------------------|-------------|---------------|------------|------------------|---------------|
| | TOTAL % CHG | TOTAL \$ | U.S. % CHG | U.S. \$ | Foreign % CHG | Foreign \$ |
| COZAAR / HYZAAR | -3% | 861 | 3% | 322 | -6% | 539 |
| JANUVIA | 30% | 491 | 19% | 354 | 68% | 137 |
| JANUMET | 72% | 173 | 42% | 122 | * | 51 |
| SINGULAIR | 5% | 1,085 | 5% | 729 | 6% | 356 |
| Vaccines: | | | | | | |
| GARDASIL | -22% | 311 | -20% | 220 | -27% | 91 |
| ROTATEQ | -6% | 127 | -9% | 113 | 36% | 13 |
| ZOSTAVAX | * | 84 | * | 84 | N/A | - |
| OTHER VIRAL VACCINES ⁽¹⁾ | 7% | 462 | 9% | 440 | -18% | 22 |
| HEPATITIS VACCINES ⁽²⁾ | 26% | 46 | 63% | 42 | -62% | 4 |
| OTHER VACCINES ⁽³⁾ | 71% | 138 | * | 99 | 17% | 39 |
| Other Reported Products: | | | | | | |
| ARCOXIA | -7% | 90 | N/A | - | -7% | 90 |
| CANCIDAS | 5% | 155 | -26% | 18 | 11% | 137 |
| COSOPT / TRUSOPT | -41% | 123 | -92% | 7 | -5% | 116 |
| CRIVAN / STOCRIN | -28% | 49 | -26% | 2 | -28% | 47 |
| EMEND | 20% | 82 | 17% | 51 | 26% | 31 |
| FOSAMAX | -22% | 276 | -59% | 39 | -8% | 237 |
| INVANZ | 3% | 73 | 5% | 39 | - | 34 |
| ISENTRESS | 84% | 197 | 68% | 95 | * | 102 |
| MAXALT | 6% | 144 | 8% | 100 | 2% | 44 |
| PRIMAXIN | -10% | 168 | 3% | 33 | -13% | 135 |
| PROPECIA | 1% | 109 | -5% | 37 | 4% | 72 |
| PROSCAR | -17% | 67 | -52% | 2 | -15% | 66 |
| TIMOPTIC / TIMOPTIC XE | -8% | 28 | * | - | -2% | 28 |
| VASOTEC / VASERETIC | -12% | 73 | N/A | - | -12% | 73 |
| ZOCOR | -10% | 141 | 3% | 17 | -12% | 124 |
| ZOLINZA | 24% | 5 | 15% | 4 | * | 1 |

* 100% or over

N/A - Not Applicable

⁽¹⁾ - Includes ProQuad, M-M-R II and Varivax.

⁽²⁾ - Includes Recombivax and Vaqta

⁽³⁾ - Includes Pneumovax, Comvax and Pedvaxhib

TOTAL SALES: VOLUME, PRICE, EXCHANGE

| | 3Q '09 | % CHG | VOL | PX | FX |
|-----------------------------------|----------|-------|-----|----|-----|
| TOTAL PHARMACEUTICAL SALES | \$ 6,050 | 2% | 2 | 2 | -3 |
| U.S. (\$ MM) | 3,455 | 4% | -1 | 4 | N/A |
| Foreign (\$ MM) | 2,595 | 0% | 6 | -1 | -6 |

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
SEPTEMBER YEAR-TO-DATE
2009

NET PRODUCT SALES DETAIL (millions of dollars)

| PRODUCT | SEPTEMBER YTD '09 vs. SEPTEMBER YTD '08 | | | | | |
|-------------------------------------|---|-------------|---------------|------------|------------------|---------------|
| | TOTAL % CHG | TOTAL \$ | U.S. % CHG | U.S. \$ | Foreign % CHG | Foreign \$ |
| COZAAR / HYZAAR | -3% | 2,606 | 3% | 958 | -6% | 1,648 |
| JANUVIA | 39% | 1,364 | 29% | 1,014 | 77% | 350 |
| JANUMET | 97% | 456 | 61% | 336 | * | 120 |
| SINGULAIR | 6% | 3,400 | 6% | 2,234 | 6% | 1,165 |
| Vaccines: | | | | | | |
| GARDASIL | -25% | 841 | -29% | 584 | -12% | 258 |
| ROTATEQ | -23% | 387 | -27% | 345 | 29% | 42 |
| ZOSTAVAX | 34% | 202 | 34% | 202 | N/A | - |
| OTHER VIRAL VACCINES ⁽¹⁾ | 6% | 1,036 | 9% | 977 | -24% | 59 |
| HEPATITIS VACCINES ⁽²⁾ | 1% | 109 | 20% | 95 | -52% | 14 |
| OTHER VACCINES ⁽³⁾ | 11% | 246 | 45% | 158 | -22% | 88 |
| Other Reported Products: | | | | | | |
| ARCOXIA | -12% | 260 | N/A | - | -12% | 260 |
| CANCIDAS | -3% | 442 | -31% | 55 | 3% | 388 |
| COSOPT / TRUSOPT | -41% | 370 | -87% | 33 | -10% | 337 |
| CRIXIVAN / STOCRIN | -31% | 154 | -21% | 8 | -31% | 146 |
| EMEND | 18% | 228 | 18% | 147 | 19% | 81 |
| FOSAMAX | -34% | 815 | -71% | 122 | -15% | 693 |
| INVANZ | 4% | 205 | 10% | 109 | -2% | 96 |
| ISENTRESS | * | 518 | 96% | 257 | * | 260 |
| MAXALT | 8% | 418 | 13% | 291 | -3% | 127 |
| PRIMAXIN | -17% | 493 | -23% | 95 | -15% | 398 |
| PROPECIA | -1% | 318 | -4% | 109 | 1% | 208 |
| PROSCAR | -13% | 219 | -55% | 4 | -12% | 214 |
| TIMOPTIC / TIMOPTIC XE | -9% | 82 | -91% | - | -4% | 82 |
| VASOTEC / VASERETIC | -17% | 226 | N/A | - | -17% | 226 |
| ZOCOR | -18% | 419 | -46% | 35 | -14% | 384 |
| ZOLINZA | 27% | 13 | 24% | 12 | 57% | 1 |

* 100% or over

N/A - Not Applicable

⁽¹⁾ - Includes ProQuad, M-M-R II and Varivax.

⁽²⁾ - Includes Recombivax and Vaqta

⁽³⁾ - Includes Pneumovax, Comvax and Pedvaxhib

TOTAL SALES: VOLUME, PRICE, EXCHANGE

| | SEP YTD '09 | % CHG | VOL | PX | FX |
|-----------------------------------|-------------|-------|-----|----|-----|
| TOTAL PHARMACEUTICAL SALES | \$ 17,335 | -3% | -1 | 2 | -4 |
| U.S. (\$ MM) | 9,662 | -3% | -8 | 4 | N/A |
| Foreign (\$ MM) | 7,673 | -2% | 8 | -2 | -8 |